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Summary
 
Lymphotoxin 
 
a 
 
(LT
 
a
 
) signals via tumor necrosis factor receptors (TNFRs) as a homotrimer
and via lymphotoxin 
 
b 
 
receptor (LT
 
b
 
R) as a heterotrimeric LT
 
a
 
1
 
b
 
2
 
 complex. LT
 
a
 
-deficient
mice lack all lymph nodes (LNs) and Peyer’s patches (PPs), and yet LT
 
b
 
-deficient mice and
TNFR-deficient mice have cervical and mesenteric LN. We now show that mice made defi-
cient in both LT
 
b
 
 and TNFR type 1 (TNFR1) lack all LNs, revealing redundancy or syner-
gism between TNFR1 and LT
 
b
 
, acting presumably via LT
 
b
 
R. A complete lack of only PPs in
mice heterozygous for both 
 
lt
 
a
 
 and 
 
lt
 
b
 
, but not 
 
lt
 
a
 
 or 
 
lt
 
b
 
 alone, suggests a similar two-ligand
phenomenon in PP development and may explain the incomplete lack of PPs seen in 
 
tnfr1
 
2/2
 
mice.
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S
 
tudies on mice genetically deficient in various second-
ary lymphoid organs are increasing our understanding
of the requirement or otherwise for these highly organized
structures in immune function, from antiviral immunity (1)
to autoimmunity (2). 
 
Hox11
 
2/2
 
 mice lack a spleen (3),
whereas 
 
aly
 
/
 
aly
 
 mutant mice lack LNs and have a disorga-
nized spleen (4, 5). Also, mice made deficient in the puta-
tive chemokine receptor BLR1 lack inguinal lymph nodes
and fail to form primary B cell follicles in the spleen (6).
Our studies have involved members of the TNF receptor
and ligand families (7, 8). Studies of TNF family members
are not only providing insight into the intricate microarchi-
tecture of immune cell responses in lymphoid organs but
also of chronic inflammatory states (9), such as the phe-
nomenon termed lymphoid neogenesis (10).
TNF-
 
a
 
 and TNF-
 
b
 
 (lymphotoxin 
 
a
 
; LT
 
a
 
)
 
1
 
 are the ar-
chetypal ligands of a growing family, which includes CD30
ligand (L), CD40L, FasL, TRAIL, and lymphotoxin 
 
b
 
(LT
 
b
 
) (11, 12). LT
 
b
 
 was discovered by virtue of its ability
to anchor LT
 
a
 
 to the cell surface, without which LT
 
a
 
 is
secreted as a homotrimer (LT
 
a
 
3
 
) (13, 14). LT
 
a/b
 
 complex
itself is a trimer with a predominant form (LT
 
a
 
1
 
b
 
2
 
) that
binds LT
 
b
 
R, and a minor form (LT
 
a
 
2
 
b
 
1
 
) that binds TNF
receptor type 1 (TNFR1) (15–17). Both forms of LT
 
a
 
 are
produced by activated lymphocytes and NK cells (12, 18).
Historically, LT
 
a
 
3
 
 is known as a factor that causes cyto-
toxicity and inflammation, and signals via TNFR1 and
TNFR2 (9, 19, 20). Although LT
 
a/b
 
 complexes do not
appear to mediate inflammation (21), pleiotropic effects of
LT
 
b
 
R cross-linking are now emerging, including cytotox-
icity (17, 22), chemokine induction (23), and integrin up-
regulation (21). Studies with 
 
lt
 
a
 
2/2
 
 mice and 
 
lt
 
b
 
2/2
 
 mice
are beginning to address the in vivo significance of these
facets of LT
 
a
 
 and LT
 
b
 
 biology (2). However, initial studies
of 
 
lt
 
a
 
2/2
 
 mice were dominated by the unexpected observa-
tion of a complete lack of LNs and Peyer’s patches (PPs), as
well as a disorganized spleen lacking follicular dendritic
cells and germinal centers (24–27). Since mice deficient in
TNFR have LNs, it had been assumed that the LT
 
a/b
 
complexes were responsible rather than LT
 
a
 
3
 
. However,
we recently showed that this explanation was not entirely
correct (28). Specifically, we determined that 
 
lt
 
b
 
2/2
 
 mice
retain mesenteric LNs (MLNs) and to a certain extent, cer-
vical LNs, both of which drain mucosal surfaces. It was
therefore a paradox that these LNs are absent in mice that
lack the LT
 
a
 
3
 
 ligand and yet they are present in mice that
lack the known receptors TNFR1 and TNFR2.
We now report that mice made deficient in both
TNFR1 and LT
 
b
 
 lack MLNs. We have thus revealed a re-
dundancy or synergism between TNFR1 and LT
 
b
 
 (pre-
sumably signaling via LT
 
b
 
R) that warrants further investi-
 
1
 
Abbreviations used in this paper:
 
 
 
dtnfr
 
2/2
 
, mice deficient in both TNFR1
and TNFR2; LT, lymphotoxin; MLN, mesenteric lymph nodes; PPs,
Peyer’s patches.
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gation in other aspects of TNFR1 and LT
 
b
 
 biology. 
 
Lt
 
a
 
2/2
 
mice and 
 
lt
 
b
 
2/2
 
 mice were derived as littermates by inter-
breeding, and unambiguously confirmed the lack of MLNs
in 
 
lt
 
a
 
2/2
 
 mice and their presence in 
 
lt
 
b
 
2/2
 
 mice. Surpris-
ingly, the latter studies also revealed a complete and specific
lack of only PPs in 
 
lt
 
a
 
1/2
 
lt
 
b
 
1/2
 
 mice. This presents a
unique mouse model for the study of gastrointestinal im-
munology and suggests that two LT
 
a
 
 ligands are involved
in PP as well as MLN development, and may explain the
incomplete lack of PPs seen in 
 
tnfr1
 
2/2
 
 mice.
 
Materials and Methods
 
Mice. lt
 
b
 
2/2
 
 and 
 
lt
 
b
 
1
 
/
 
1
 
 wild-type mice (expanded from orig-
inal littermates of 
 
lt
 
b
 
2/2
 
 mice) are those described previously
(28). A breeding pair of 
 
lt
 
a
 
2/2
 
 mice (24) was obtained from
Nancy Ruddle (Yale University Department of Epidemiology
and Public Health, Yale University), derived originally from
David Chaplin (Washington University, St. Louis, MO). Mice
deficient in both TNFR1 and TNFR2 (
 
dtnfr
 
2/2
 
) represent mice
derived by interbreeding 
 
tnfr1
 
2/2
 
 mice with 
 
tnfr2
 
2/2
 
 mice (29).
Various other knockout combinations were obtained by inter-
breeding. All mice were on a mixed background of C57BL/6 and
129/Sv. Breeding pairs of C57BL/6 Ly5.1 (CD45.1) mice were
purchased from Clarence Reeder (Frederick Cancer Research In-
stitute, Frederick, MD). All mice were maintained at Yale Uni-
versity in specific pathogen-free conditions. All procedures were
conducted in accordance with Yale animal care and use guide-
lines.
LT
 
b
 
 genotyping was by PCR using three oligonucleotides,
yielding 
 
z
 
120- and 330-bp products for the 
 
lt
 
b
 
1
 
 and 
 
lt
 
b
 
2
 
 
 
alleles,
respectively. The oligonucleotide sequences are: LT
 
b
 
for, 5
 
9
 
-GAG-
ACAGTCACACCTGTTG-3
 
9
 
; LT
 
b
 
rev, 5
 
9
 
-CCTGTAGTCCA-
CCATGTCG-3
 
9
 
; and LT
 
b
 
neo, 5
 
9-CTTGTTCAATGGCCGA-
TCC-39. TNFR1 and TNFR2 genotyping was by Southern blot
analysis as described elsewhere (29).
Bone Marrow Chimeras. Hosts were exposed to 950 rads at 6–8
wk of age and, 1 d later, were given 2 3 106 total nucleated bone
marrow cells intravenously in 0.2 ml of PBS. Bone marrow was
from sex-matched 8–12-wk-old C57BL/6 Ly5.1 mice. 8 wk after
irradiation, the relative ratio of CD45.11 donor cells versus
CD45.21 host cells in peripheral blood was determined by fluo-
rocytometry. Both biotin-conjugated anti-CD45.1 and FITC-
conjugated anti-CD45.2 were from PharMingen (San Diego,
CA). The degree of chimerism was .95% in all cases. 9–10 wk
after irradiation, recipients were challenged intraperitoneally with
0.1 mg of chicken g globulin adsorbed to alum in 0.2 ml of PBS
and were culled 12 d later.
Pathology. Visualization of bracheal, axillary, inguinal, and
popliteal LNs (30) was aided in some experiments by injecting 50 ml
of india ink into each footpad of the mice 3–4 h before culling.
The prominence of PPs was greatly increased by immersing the
intestine in 10% (vol/vol) acetic acid for 5 min before preserva-
tion in 10% neutral-buffered formalin. Hematoxylin and eosin
staining was done on paraffin sections using standard procedures.
Immunohistology. Mice were challenged intraperitoneally at
6–8 wk of age with 0.1 mg of chicken g globulin adsorbed to
alum in 0.2 ml of PBS. Spleens and MLNs were harvested 12 d
later and frozen in O.C.T. compound using a dry-ice/methylbutane
bath. 5-mm thick sections were cut onto silanized glass slides and
fixed in cold acetone for 5 min before storage at 2708C. For
staining, sections were allowed to thaw for 10 min and then rehy-
drated in PBS for 20 min. Endogenous peroxidase was inactivated
with 0.3% hydrogen peroxide for 5 min and the sections were
then washed with PBS for 10 min. Blocking was with PBS/3%
BSA/0.1% (vol/vol) Tween 20 for 30 min. Staining for IgD used
rat anti–mouse IgD (Southern Biotechnology Associates, Bir-
mingham, AL), followed by biotin-conjugated goat anti–rat IgG
(Southern Biotechnology Associates) and then b-galactosidase–
conjugated avidin (Vector Laboratories, Burlingame, CA). Wash-
ing between layers was with PBS/0.1% (vol/vol) Tween 20 be-
fore reblocking as above. Germinal centers were stained using
horseradish peroxidase–conjugated peanut agglutinin (EY Labo-
ratories, San Mateo, CA; reference 31). IgM detection was with
alkaline phosphatase–conjugated goat anti–mouse IgM (Southern
Biotechnology Associates). Follicular dendritic cells were revealed
with biotin-conjugated anticomplement receptor 1 (PharMingen,
San Diego, CA; reference 32), followed by alkaline phosphatase–
conjugated streptavidin (Zymed, South San Francisco, CA). Sub-
strates for b-galactosidase, horseradish peroxidase, and alkaline
phosphatase were HistoMark X-Gal (Kirkegaard and Perry Labs.,
Inc., Gaithersburg, MD), diaminobenzidine-brown (Zymed), and
HistoMark Red (Kirkegaard and Perry Labs., Inc.), respectively.
Results
Lta2/2 Littermates of ltb2/2 Mice Lack MLNs. Initial re-
ports of the phenotype of two independently generated
lta2/2 mouse strains differed in that one indicated that
MLNs were absent (24), whereas the other indicated that
lymphoid structures were present in the mesentery of 4 out
of 14 mice (25). Most recently, among z500 lta2/2 mice
examined for MLNs, only 10 had a single MLN (33). It
was thus suggested that the frequency of occurrence of
MLNs in lta2/2 mice may vary depending on how the
mice are housed (33). If true, this would perhaps apply
equally to ltb2/2 mice, which we described as consistently
having MLNs (28). Furthermore, Alimzhanov et al. inde-
pendently generated ltb2/2 mice and found that only
z75% of these mice have MLNs (34). It was therefore also
conceivable that there are effects of background genes, al-
though all mice examined were on a mixed background of
129/Sv and C57BL/6. The studies here were begun to ex-
amine these issues and determine why ltb2/2 mice have
MLNs despite the fact that lta2/2 mice mostly do not.
The lta and ltb genes are separated by only z6 kbp in
the MHC locus (12). Thus, we reasoned that it would be
possible to generate lta2/2 mice and ltb2/2 mice as litter-
mates by interbreeding mice which are heterozygous for
both lta and ltb (lta1/2ltb1/2 mice). In this way, 137 prog-
eny were generated and genotyped as described in Materi-
als and Methods. Lta2/2, ltb2/2, and lta1/2ltb1/2 mice oc-
curred in a relatively normal Mendelian fashion (n 5 31,
40, and 66, respectively). Some of these mice were exam-
ined at 6–8 wk of age. Lta2/2 mice did not have MLNs (n 5
14), whereas almost all of their ltb2/2 littermates did (n 5
25). A single ltb2/2 mouse out of 25 appeared to lack
MLNs.
Lymphotoxin Gene Dosage Effect in PP Development.
Unlike  lta2/2 and ltb2/2 mice, the above heterozygous
lta1/2ltb1/2 mice had all LNs (n 5 30), except that two1979 Koni and Flavell
mice had only one inguinal LN and one mouse had none.
Surprisingly, however, lta1/2ltb1/2 mice showed a com-
plete lack of PPs (n 5 30), whereas both lta1/2 mice (n 5
13) and ltb1/2 mice (n 5 14) have PPs as well as all LNs.
Having made this observation, we examined lta1/2ltb1/2
mice further. At 6–8 wk of age, the gross spleen architec-
ture was normal by hematoxylin and eosin histology (data
not shown). Immunohistology for complement receptor 1
in the spleen (done as previously described; reference 28)
revealed the presence of follicular dendritic cells (data not
shown). Also, splenic germinal centers were formed in discrete
B cell follicles after intraperitoneal challenge, except there
Figure 1. Lta1/2ltb1/2 mice have relatively normal lymphoid organ architecture. Mice were challenged intraperitoneally with 0.1 mg of chicken g
globulin adsorbed to alum and culled 12 d later. Spleen (A, C, and E) and MLNs (B, D, and F) sections were stained for IgM (red), IgD (blue) and peanut
agglutinin–binding germinal centers (brown). A and B, wild-type; C and D, ltb2/2; E and F, lta1/2ltb1/2. Original magnification, 365 and 3150 for
spleen and MLN, respectively.1980 Lymphotoxin b Functions in Mesenteric Lymph Node Development
appeared to be some disorganization among IgM1IgDlo/2
marginal zone B cells (Fig. 1 E). Lta2/2 mice (24–28) and
ltb2/2 mice (28, 34) have severe defects in all of these as-
pects of lymphoid organogenesis.
The organization of the MLNs of lta1/2ltb1/2 mice was
also relatively normal (Fig. 1 F). As previously noted (28),
the organization of the MLNs of ltb2/2 mice is not normal
in that there appears to be a generalized B cell infiltration,
but B cell follicles are found around the rim of MLNs and
germinal center B cell clusters are formed despite the ab-
sence of follicular dendritic cells (reference 28; Fig. 1 D).
The lack of PPs in lta1/2ltb1/2 mice was confirmed in
progeny from intercrossing lta2/2 mice with ltb2/2 mice (n 5
4). Bone marrow chimeras were also generated using wild-
type bone marrow, to examine whether or not the lack of
PPs was reversible. None of the lta1/2ltb1/2 recipients
showed any sign of PPs 10–12 wk after irradiation, but
they did have LNs (n 5 9). None of the lta2/2 recipients
had MLNs (n 5 8), but all of the ltb2/2 recipients did (n 5
11). None of the lta2/2 recipients or ltb2/2 recipients had
PPs. Ltb1/1 wild-type recipients had MLNs and PPs (n 5 4).
TNFR1 Is Involved in MLN Development. Both  ltb2/2
mice and dtnfr2/2 mice have MLNs, and yet lta2/2 mice do
not. This led us to propose that LTa may act without LTb
(i.e., as LTa3) via an as yet unidentified receptor (28). To
test this hypothesis, we generated mice lacking both LTb
and TNFR and examined them for the presence of MLNs.
Since TNFR-deficient mice were originally obtained as
dtnfr2/2 mice, the first mice generated here were ltb2/2
dtnfr2/2 mice. At 6–8 wk of age, ltb2/2dtnfr2/2 mice
showed a complete lack of MLNs (n 5 10), whereas ltb1/2
dtnfr2/2 mice still had MLNs (n 5 5).
In a similar way to lta2/2 mice, it is conceivable that the
apparent absence of MLNs in ltb2/2dtnfr2/2 mice is due to
a possible lack of immune competence and/or lymphocyte
homing, and that this might be reversed after reconstitution
with wild-type bone marrow. We therefore generated
wild-type bone marrow chimeras. However, none of the
bone marrow chimeras had MLNs 10–12 wk after recon-
stitution (n 5 11).
In the meantime, we also generated ltb2/2tnfr12/2 and
ltb2/2tnfr22/2 mice. The latter had MLNs (n 5 4) but ltb2/2
tnfr12/2 mice clearly did not (n 5 5). Most ltb2/2tnfr11/2
littermates (n 5 5) had one small MLN (Fig. 2). One ltb2/2
tnfr11/2 littermate did not appear to have MLNs, whereas
another had two small MLNs. This may be explained by
the fact that tnfr1 heterozygosity is known to result in a
partial phenotype at least in some respects (35), but at the
same time ltb1/2tnfr11/2 mice had MLNs of a normal size
(n 5 13).
Discussion
The study reported here extends our knowledge of the
roles of TNF ligand/receptor family members in lymphoid
organogenesis (Table 1). Based on several observations, we
had previously hypothesized that both TNFR1 and LTbR
may be involved in PP development (28). First, both lta2/2
mice (24, 25) and ltb2/2 mice (28, 34) completely lack PPs.
Second, Rennert et al. observed a complete lack of PPs in
mice administered recombinant soluble LTbR in utero
(36). Third, tnfr12/2 mice lack PPs but have reduced num-
bers of residual lymphoid aggregates (37). Defective PP de-
velopment was also reported recently with an indepen-
dently generated tnfr12/2 mouse strain (29). Others reported
that tnfr12/2 mice have PPs but that they appear flattened
due to a lack of B cell follicle structures (38). However,
even this study noted that tnfr12/2 mice have on average
only two to four such PPs compared with six to eight PPs
in the wild-type control mice (38).
In this study, we show the existence of a gene dosage ef-
fect that is consistent with a role for both TNFR1 and
LTbR in PP development. That is, lta1/2ltb1/2 mice spe-
cifically lack only PPs, but lta1/2 mice and ltb1/2 mice do
not. If LTa and LTb form a single species that signals via a
single receptor, it might be expected that either LTa or
LTb would be the limiting factor and that heterozygosity
in either lta or ltb alone should result in the lack of PPs
seen in lta1/2ltb1/2 mice. However, this is not the case.
Only when both lta and ltb are heterozygous does insuffi-
ciency become evident. One interpretation would be that
two ligands (e.g., LTa3 and LTa1b2 signaling via TNFR1
Figure 2. Ltb2/2tnfr11/2 mice have defective MLN development. ltb2/2
tnfr2/2 mice completely lack MLNs and ltb2/2tnfr11/1 littermates have
MLN of apparently normal size and number (top), but ltb2/2tnfr11/2 lit-
termates most often have only a single, small MLN (bottom). Hematoxylin
and eosin histology; original magnification: 315.1981 Koni and Flavell
and LTbR, respectively) are involved in PP development,
and that heterozygosity in either one or the other alone is
not enough to cause a complete loss of PP development.
This two-receptor model might therefore provide an explana-
tion for the partial defect in PP development seen in tnfr12/2
mice.
Clearly, our results show that both TNFR1 and LTb are
involved in MLN development, even though both tnfr12/2
mice and ltb2/2 mice have MLNs. TNFR1 also functions
independently of TNFR2 in this regard, as ltb2/2tnfr22/2
mice still have MLNs. We have thus revealed a previously
unappreciated relationship between TNFR1 and LTb
(presumably acting via LTbR). An explanation for the lack
of MLN in lta2/2 mice might therefore be that LTa defi-
ciency actually eliminates both ligands of the relationship (i.e.,
LTa3 and LTa1b2 signaling via TNFR1 and LTbR, re-
spectively). LTa3 itself is not believed to bind LTbR (16, 17).
However, having said this, it has been indicated that
ltbr2/2 mice lack MLNs (34). Thus, the relationship be-
tween TNFR1 and LTbR may be one of synergism with
LTbR as the dominant partner. At the same time, the pres-
ence of MLN in ltb2/2 mice would imply that LTbR has a
ligand besides the LTa/b complex. Indeed, Mauri et al.
have very recently described a new LTbR ligand (LIGHT)
as well as a new LTa3 receptor, the herpesvirus entry me-
diator, expressed by lymphocytes (39).
The molecular basis for the relationship between TNFR1
and LTb (presumably via LTbR) remains to be deter-
mined. It is conceivable that TNFR1 and LTbR signaling
in MLN development is simultaneous and that they inter-
act at the level of intracellular signal transducers. Certainly,
activation of LTbR has been shown to potentiate TNF-a
cytotoxicity, possibly reflecting cross-talk between signal-
ing pathways (17, 22). Ligation of LTbR causes recruit-
ment of TNFR-associated factor family members (40–42),
and activation of NF-kB and cell death by distinct signaling
pathways (42, 43).
Thus far, our studies of ltb2/2 mice have evaluated the
defects in lymphoid organogenesis (reference 28 and this
study). We are now beginning to examine whether or not
LTb has roles in vivo in other respects. Certainly, in vitro
studies have shown that signaling via LTbR causes cyto-
toxicity to some cell lines (17, 22), chemokine expression
(23), and integrin upregulation (21). It remains to be seen
whether or not the relationship between TNFR1 and LTb
(presumably via LTbR) in gut-associated lymphoid tissue
development extends to any other facets of biology. With
this in mind, caution is advised when interpreting the in
vivo role (or rather, apparent lack thereof) of LTb and
TNFR1 based on studies of ltb2/2 mice and tnfr12/2 mice
alone.
Finally, lta1/2ltb1/2 mice may prove to be a useful PP-
less mouse model, not only for the study of gastrointestinal
infection, but also of oral tolerance, oral vaccination, and
chronic disorders such as inflammatory bowel disease (44–
46). Lta1/2ltb1/2 mice are being further characterized, par-
ticularly with respect to the subtle defect observed in
splenic marginal zone organization. Although it remains
possible that lta1/2ltb1/2 mice have other as yet unidenti-
fied defects, unlike any other previously described mouse,
these mice specifically and completely lack only PPs and do
not appear to have any of the major abnormalities associ-
ated with lta2/2 and ltb2/2 mice.
Table 1. Phenotypes of Mice Made Genetically Deficient in TNF Ligand/Receptor Family Members
Family Members lta2/2 ltb2/2 tnfa2/2 tnfr12/2 lta1/2ltb1/2 ltb2/2tnfr12/2
Spleen
Primary B cell follicles 22 2 2 1 ND
Marginal zone 2 2 1 1 1/2 ND
Germinal centers 22 2 2 1 ND
Follicular dendritic cells 22 2 2 1 ND
MLNs 21 1 1 1 2
Primary B cell follicles 1/2 ND 21
Germinal centers 1/2 ND 21
Follicular dendritic cells 2 ND 21
Cervical LN 2 1/22 1 1 1 2
Inguinal LN 2 2 1 1 1/2 2
Other LN 22 1 1 1 2
PPs 2 2 1/2 1/2 2 2
This table is based on citations in the text and others as summarized elsewhere (8), as well as the findings from this study. Unlike lta1/2ltb1/2 double
heterozygous mice, lta1/2 mice and ltb1/2 mice have PPs as well as all LNs. Other features of the phenotype of lta1/2 mice and ltb1/2 mice have
not been determined. Also, although ltb2/2tnfr12/2 mice do not have MLNs, ltb2/2tnfr22/2 mice do.1982 Lymphotoxin b Functions in Mesenteric Lymph Node Development
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